IP Library Granted Patent US 7,368,441
Granted Patent B2
US 7,368,441 · App. 11/468,605 · Granted May 6, 2008

Method of increasing intracellular concentrations of phosphate and increasing the force of muscular contractions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,368,441
App. No.
11/468,605
Granted
May 6, 2008
Kind
B2
Abstract

The present invention relates to a method of increasing the intracellular concentration of phosphate by employing 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid as vehicle and method to transport Phosphate into the cell. The increase in intracellular phosphate increases the availability of Adenosine Triphosphate and phosphocreatine, thereby leading to an increase in the anaerobic energy supply resulting in longer endurance and more forceful muscular contractions.

Claims (14)

1. A method of increasing intracellular phosphate, comprising the steps of:

selecting a composition comprising creatine and fine-milled 2-(carbamimidoyl-methyl-amino)ethoxyphosphonic acid particles admixed with a comestible carrier, at least 50% of said 2-(carbamimidoyl-methyl-amino) ethoxyphosphonic acid particles having a particle size between 2-50 nm; and

orally administering to a human an effective amount of said composition to increase intracellular concentration of phosphate.

2. The method according to claim 1 , wherein said phosphate is 2,3-diphosphoglycerate.

3. The methods according to claims 1 or 2 , wherein at least 80% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

4. The methods according to claims 1 or 2 , wherein at least 90% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

5. The method according to claim 1 , wherein said phosphate is increased in red blood cells.

6. The method according to claim 5 , wherein said phosphate is 2,3-diphosphoglycerate.

7. The methods according to claim 6 , wherein at least 80% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

8. The methods according to claim 6 , wherein at least 90% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

9. The method according to claim 1 , wherein said phosphate is increased in muscle cells.

10. The method according to claim 9 , wherein said phosphate is 2,3-diphosphoglycerate.

11. The methods according to claim 10 , wherein at least 80% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

12. The methods according to claim 10 , wherein at least 90% of said fine-milled 2-(carbomimidoyl-methyl-amino)ethoxyphosphic acid particles have a particle size between 2-50 nm.

Assignments (14)
RELEASE OF SECURITY INTEREST Recorded May 29, 2026
From: ROYAL BANK OF CANADA
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 075647/0267 →
SECURITY AGREEMENT Recorded May 28, 2026
From: LOVATE HEALTH SCIENCES INTERNATIONAL INC.; NORTHERN INNOVATIONS HOLDING CORP.; LOVATE HEATH SCIENCES U.S.A. INC.
To: FGI WORLDWIDE LLC
Reel/Frame 075641/0893 →
MERGER AND CHANGE OF NAME Recorded Sep 30, 2024
From: ROYAL BANK OF CANADA; HSBC TRUST COMPANY (CANADA); HSBC MORTGAGE CORPORATION (CANADA); HSBC FINANCE MORTGAGES INC.; HSBC BANK CANADA + 4 OTHERS NOTED ABOVE IN 'CONVEYING PARTY DATA'
To: ROYAL BANK OF CANADA/BANQUE ROYALE DU CANADA
Reel/Frame 069072/0683 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NUMBER OF PATENT NUMBER 7,645,812 TO 7,465,812 PREVIOUSLY RECORDED AT REEL: 059662 FRAME: 0958. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Apr 26, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059793/0777 →
SECURITY INTEREST Recorded Apr 21, 2022
From: NORTHERN INNOVATIONS HOLDING CORP.
To: HSBC BANK CANADA
Reel/Frame 059662/0958 →
CHANGE OF NAME Recorded Aug 14, 2016
From: 2508304 ONTARIO LIMITED
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039673/0027 →
CHANGE OF NAME Recorded Aug 14, 2016
From: 2462096 ONTARIO LIMITED
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039672/0990 →
CHANGE OF NAME Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS HOLDING CORP.
To: OLD NORTHERN INNOVATIONS CORP.
Reel/Frame 039672/0994 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2016
From: OLD NORTHERN INNOVATIONS CORP.
To: 2462096 ONTARIO LIMITED
Reel/Frame 039427/0313 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 14, 2016
From: OLD NORTHERN INNOVATIONS CORP.
To: 2508304 ONTARIO LIMITED
Reel/Frame 039427/0326 →
MERGER Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS HOLDING CORP.
To: OLD NORTHERN INNOVATIONS CORP.
Reel/Frame 039427/0336 →
MERGER Recorded Aug 14, 2016
From: NORTHERN INNOVATIONS AND FORMULATIONS CORP.
To: NORTHERN INNOVATIONS HOLDING CORP.
Reel/Frame 039672/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 4, 2016
From: EVERSLIM FORMULATIONS LTD.
To: NORTHERN INNOVATIONS AND FORMULATIONS CORP.
Reel/Frame 039347/0317 →
MERGER Recorded Aug 4, 2016
From: APLODAN FORMULATIONS LTD.
To: EVERSLIM FORMULATIONS LTD.
Reel/Frame 039347/0189 →